Holen Sie sich die Stockscreener-App
3.63
2.69%
-0.07
Schlusskurs vom Vortag:
$3.70
Offen:
$3.67
24-Stunden-Volumen:
43,738
Relative Volume:
0.34
Marktkapitalisierung:
$4.56M
Einnahmen:
$204.80K
Nettoeinkommen (Verlust:
$-8.27M
KGV:
-0.399
EPS:
-9.097
Netto-Cashflow:
$-2.63M
1W Leistung:
+2.29%
1M Leistung:
-37.92%
6M Leistung:
-49.99%
1J Leistung:
-53.54%
1-Tages-Spanne:
$3.55
$3.76
1-Wochen-Bereich:
$3.43
$3.91
52-Wochen-Spanne:
$3.40
$12.05
Addex Therapeutics Ltd Adr Stock (ADXN) Company Profile
Firmenname
Addex Therapeutics Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare ADXN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADXN
Addex Therapeutics Ltd Adr
|
3.60 | 4.68M | 204.80K | -8.27M | -2.63M | -9.097 |
VRTX
Vertex Pharmaceuticals Inc
|
522.72 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.64 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Addex Therapeutics Ltd Adr Stock (ADXN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Addex Therapeutics Ltd Adr Aktie (ADXN) Neueste Nachrichten
Kalinichev Mikhail Receives 306,765 Shares and 200,000 Derivative Securities from Addex Therapeutics - Kalkine Media
Hill Raymond George Discloses Award and Disposal of 1.37M Addex Therapeutics Shares and Derivative Securities - Kalkine Media
Hill Raymond George Announces Award and Disposal of 1.37M Addex Therapeutics Shares and Derivative Securities - Kalkine Media
Manke Isaac Adjusts Holdings in Addex Therapeutics with 219,561 Shares and 50,000 Derivatives on September 2, 2026 - Kalkine Media
Timothy Mark Dyer Discloses 8.98% Stake in Addex Therapeutics (NASDAQ: ADXN) - Kalkine Media
Addex Therapeutics LtdADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Addex Therapeutics Ltd Sponsored ADR Revenue Breakdown – MUN:APE1 - TradingView
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness - Barchart.com
Addex Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ADXN) - TradingView
Enterprise value to revenue forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Price to earnings forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Price to sales forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Earnings call transcript: Addex Therapeutics trims loss in Q1 2026 as cash burn stays low - Investing.com India
Addex Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 - Barchart.com
Addex Convenes Annual General Meeting 2026 - Barchart.com
ADXN - Finviz
Addex Therapeutics (NASDAQ: ADXN) flags tight cash runway and heavy partner reliance - Stock Titan
Addex Therapeutics H2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Addex Therapeutics H2 2026 reveals strategic shifts By Investing.com - Investing.com India
Earnings call transcript: Addex Therapeutics H2 2026 reveals strategic shifts - Investing.com
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update - Barchart.com
Addex Therapeutics announces GABAB PAM candidate data - TipRanks
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model - Barchart.com
Unusual VolumeStock ScreenerNews - Finviz
Addex Therapeutics says spin-out company to complete NTX-253 study in Q2 - TipRanks
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model - Barchart.com
Addex Therapeutics Short Interest Drops in March - National Today
New HighStock ScreenerSnapshot - Finviz
Top GainersStock ScreenerSnapshot - Finviz
JX Luxventure Group Inc (NASDAQ:JXG) Short Interest Up 140.3% in February - Defense World
Short Interest in Raia Drogasil S.A. (OTCMKTS:RADLY) Increases By 138.8% - Defense World
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) Short Interest Up 142.0% in February - Defense World
Short Interest in Intrum AB (publ) (OTCMKTS:ITJTY) Grows By 140.2% - Defense World
Breakwave Tanker Shipping ETF (NYSEARCA:BWET) Short Interest Update - Defense World
Solidion Technology Inc. (NASDAQ:STI) Sees Significant Growth in Short Interest - Defense World
Addex Therapeutics (NASDAQ:ADXN) Trading 2% Higher – Here’s Why - Defense World
Addex Therapeutics (ADXN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Addex Therapeutics Earnings Call: Progress Amidst Financial Challenges - The Globe and Mail
Addex Therapeutics Reports Q3 2025 Financial Results - The Globe and Mail
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Charcot Marie Tooth Disease Market on Track for Major Expansion by 2034, According to DelveInsight | DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharma - Barchart.com
Addex Therapeutics Reports Significant Loss Amid Financial Challenges - The Globe and Mail
ADXN SEC FilingsAddex Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Addex Therapeutics (ADXN) Trading Halted Due to Volatility | ADX - GuruFocus
Addex Therapeutics Ltd_December 31, 2024 - SEC.gov
Aspire Biopharma (ASBP) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Addex Therapeutics Ltd (ADR) (ADXN) Live Share Price, Invest From India - INDmoney
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year? - Yahoo Finance
Finanzdaten der Addex Therapeutics Ltd Adr-Aktie (ADXN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):